EL7.AI
StocksMedium•17 November 2026•
3 min read

Iridex cuts 2026 revenue outlook to $46–48 million after quarterly sales decline

Key Facts

1Iridex revenue was $10.2 million in the third quarter of 2026, down 19%.
2The company cut its 2026 revenue outlook to $46–48 million from $51–53 million.
3Net loss was $1.4 million, or $0.08 per share, compared with $1.6 million, or $0.09 per share, a year earlier.
4Cash and cash equivalents were $3.7 million on October 3, 2026, down $1 million from July 4.

Iridex reported on November 17 results for the third quarter ended October 3, 2026, posting revenue of $10.2 million, down 19% from the same period a year earlier. The company said in a statement published by GlobeNewswire that net loss was $1.4 million, or $0.08 per share, compared with $1.6 million, or $0.09 per share, a year earlier. The results came alongside a cut to its fiscal 2026 revenue outlook to a range of $46 million to $48 million. In the second quarter, the company had maintained its outlook at $51–53 million. The new range excludes Middle East revenue, according to the company’s statement.

Iridex attributed the revenue decline to weaker-than-expected customer demand in Europe and Asia, along with delayed orders late in the quarter. It said its distributors were working through probe inventory, while regulatory challenges continued to weigh on the business. Retinal product revenue was $5.1 million, compared with $6.7 million in the year-earlier period. The company linked the decline to international markets and external headwinds. These factors explain part of the revenue decline, while the statement also cited delayed distributor orders at quarter-end.

The Cyclo G6 product family generated revenue of $3.2 million, compared with $3.5 million a year earlier. Sales of probes in this family totaled about 11,900 in the quarter, compared with 14,900 in the same period a year earlier. That represents a decline in units sold alongside a drop in the product’s overall revenue. Among the figures reported by the company, distributors’ efforts to work through probe inventory feature in the context of slower demand and delayed orders. The statement did not specify how much each of these factors contributed to probe sales.

Operating expenses were $5.5 million in the third quarter, compared with $5.4 million a year earlier, a level the company described as broadly flat. But the adjusted loss before interest, taxes, depreciation and amortization was $0.6 million, compared with a loss of $0.1 million in the third quarter of 2025. On liquidity, cash and cash equivalents stood at $3.7 million on October 3. That was $1 million below the level on July 4, 2026. The company said cash use during the quarter was $1 million.

Iridex announced that it had completed the move of its headquarters to San Jose and said the relocation is expected to generate annual savings of about $600,000. It also said moving production of its key products to contract manufacturers is expected to be the next driver of margin expansion through 2027. On liquidity, the company said it expects cash use to decline significantly in the fourth quarter as sales improve and it reverses its safety-stock build. The statement linked this to stronger sales in the coming quarter and the consumption of inventory accumulated during the build. The new annual revenue outlook continues to exclude Middle East revenue.

The outlook revision follows the company’s second-quarter revenue of $12.6 million, compared with $13.6 million in the second quarter of 2025, when it reaffirmed its annual range at $51–53 million. In an earlier filing with the U.S. Securities and Exchange Commission, Iridex said its stock’s bid price had remained below the $1 minimum for 30 consecutive business days. Nasdaq gave it until February 23, 2027, to regain compliance with the bid-price requirement. That deadline gives the company a set date to address its listing status as it cuts its revenue outlook and pursues cost reductions. The next operational milestones identified by the company include the impact of headquarters relocation savings and the shift of manufacturing to contract manufacturers, with margin expansion expected to continue through 2027.

Open on chart